hotspot -WSS

hotspot

author：fashion 2025-10-03 00:39:51 - browse：94156

Novo Nordisk headquarters -- health coverage from STAT — Novo Nordisk's headquarters, outside Copenhagen, Denmark. LISELOTTE SABROE/Scanpix/AFP via Getty Images

Novo Nordisk is pausing ads for its obesity drug Wegovy as it struggles to keep up with surging demand, the latest hurdle in its rollout of the weight loss drug.

“To avoid stimulating further demand for this medicine, we’re pausing some key Wegovy promotional efforts,” the Danish drugmaker said in an emailed statement. “We are pausing all local television advertising and postponing planned national television advertising for Wegovy. We are also assessing our promotional efforts to healthcare professionals and adjusting accordingly.” The news was earlier reported by Endpoints.

Wegovy, which contains the active ingredient semaglutide, has become immensely popular for its effectiveness in helping people lose weight and is helping usher in what many see as a sea change in obesity treatment. Its sister drug for diabetes, Ozempic, has also been in demand for a similar effect on weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： What will Novo Nordisk's VC do with its influx of cash?

WSS

Pfizer's RSV vaccine recommended for approval in Europe

'The View' co

European officials brace for rough respiratory virus season

New oral drug delivery patch is modeled after octopus tentacles

Flu, Covid vaccination rates decline, new survey data show

The biotech scorecard for the 2nd quarter: 12 industry events to watch

focus

hotspot

focus

Virginia high school admissions case could be legal follow

Health insurers' Q3 question: how much care are people getting?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What we owe ALS patients — and why one company fell short

In age of alternative facts, a scholarly course on calling out crap

Hey, doctors: Don't be no

How one medical school became remarkably diverse

Setback for rare diseases as Taysha Gene Therapies pulls back

Moonlake's readout produced a cash windfall. Risks remain

What is artificial intelligence? Experts weigh in

explore

Health insurers' Q3 question: how much care are people getting?

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

New oral drug delivery patch is modeled after octopus tentacles

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Why the advice to take all your antibiotics may be wrong

Study points to new risk in gene therapy death of Terry Horgan

entertainment

leisure time

hotspot

hotspot